Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV
NCT01368497Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Sep 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of entecavir, peginterferon alfa-2a in Chronic Hepatitis B (CHB), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Sep 2012; status: completed.
02
Drugs
entecavirpeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01368497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01368497.